Meeting
2022 ASCO Annual Meeting
Panel Question and Answer
Presenter
Panel Discussion
ASCO
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Case-Based Panel
Session Title
Pharmacogenetic Testing to Personalize Cancer Therapy: Ready or Not?
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology,Gastrointestinal Cancer—Colorectal and Anal,Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Similar Videos & Slides
Videos & Slides
2022 ASCO Annual Meeting
Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis.
Speaker: Erica C. Nakajima, MD, MD
Videos & Slides
2021 ASCO Annual Meeting
A phase II trial of chemotherapy plus pembrolizumab in patients with advanced NSCLC previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.
Speaker: Nikhil Shukla, MD, MS
Videos & Slides
2021 ASCO Annual Meeting
PD-(L)1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer patients with high PD-L1 expression: A network meta-analysis.
Speaker: Margarita Majem, MD, PhD
Speaker: Anthony T. C. Chan, MD